Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 41.11 USD 7.48% Market Closed
Market Cap: 15.8B USD
Have any thoughts about
Moderna Inc?
Write Note

Moderna Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Moderna Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Moderna Inc
NASDAQ:MRNA
Revenue
$5.1B
CAGR 3-Years
-25%
CAGR 5-Years
129%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Moderna Inc
Revenue Breakdown

Breakdown by Geography
Moderna Inc

Total Revenue: 6.8B USD
100%
Rest Of World: 3.6B USD
52.5%
United States: 1.9B USD
27.7%
Europe: 1.4B USD
19.8%

Breakdown by Segments
Moderna Inc

Total Revenue: 6.8B USD
100%
Net Product Sales: 6.7B USD
97.4%
Other Revenue: 177m USD
2.6%
Grant Revenue: 94m USD
1.4%
Collaboration Revenue: 83m USD
1.2%
Show More
Show Less

Moderna Inc
Glance View

Market Cap
15.8B USD
Industry
Biotechnology

Moderna Inc. emerged as a game-changer in the biotechnology sector, leveraging its groundbreaking mRNA technology to develop innovative vaccines and therapies. Founded in 2010, the company initially focused on utilizing messenger RNA to instruct cells to produce proteins that could fight off diseases. This vision became a reality when Moderna's COVID-19 vaccine received emergency use authorization in late 2020, marking a pivotal moment not only for public health but for the firm itself. As a player in the rapidly evolving pharmaceutical landscape, Moderna's success has spurred substantial recognition and investment, showcasing its potential to address not just infectious diseases but also other serious health conditions such as cancer and rare genetic disorders. From an investment perspective, Moderna embodies a blend of growth potential and cutting-edge technology, highlighted by its strong pipeline of mRNA-based therapeutics. With significant revenue generated from its COVID-19 vaccine, the company has been able to reinvest in research and development, enhancing its capabilities to tackle various diseases. Furthermore, as global vaccination efforts continue, Moderna's valuable partnerships with governments and healthcare organizations position it well for sustainable growth. Investors should consider the company's innovative approach, robust financial performance, and the potential for continued advancements in mRNA technology as key factors that could drive long-term value in an increasingly competitive biotech arena.

MRNA Intrinsic Value
54.14 USD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Moderna Inc's Revenue?
Revenue
5.1B USD

Based on the financial report for Sep 30, 2024, Moderna Inc's Revenue amounts to 5.1B USD.

What is Moderna Inc's Revenue growth rate?
Revenue CAGR 5Y
129%

Over the last year, the Revenue growth was -44%. The average annual Revenue growth rates for Moderna Inc have been -25% over the past three years , 129% over the past five years .

Back to Top